Finafloxacin Composition for Resistant Otic Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for otic infections, particularly those caused by quinolone-resistant bacteria, are less effective due to microbial resistance, and existing quinolone antibiotics are not optimally suited for the acidic environment of the external ear, which poses a challenge in effectively treating conditions like acute otitis externa and acute otitis media with tympanostomy tubes.
Innovation Solution
A composition comprising finafloxacin at an acidic pH, which enhances antimicrobial efficacy and penetration, thereby effectively treating otic infections while minimizing the risk of inner ear toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional quinolone antibiotics are used to treat otic infections, then antimicrobial activity is provided, but efficacy is reduced against quinolone-resistant bacteria
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of quinolone antibiotics to create finafloxacin, which has altered pharmacological properties including enhanced activity against quinolone-resistant bacteria. The structural modifications enable the compound to overcome resistance mechanisms while maintaining efficacy against susceptible strains.
Solution Approach 2:
The invention combines finafloxacin with hydroxypropyl cellulose to create a composite formulation that optimizes both antimicrobial activity and delivery to the infection site. This composite approach enhances therapeutic effect while managing resistance issues.
2Object-affected harmful factors
If topical antimicrobial compositions are used for otic infections, then systemic side effects are avoided, but penetration and efficacy in the acidic ear environment are reduced
Solution Approach 1:
The patent utilizes the acidic pH environment of the external ear (pH 5.0-7.0) to enhance finafloxacin stability and activity. The compound maintains efficacy in this acidic environment, and the formulation is specifically designed to leverage these conditions rather than对抗 them, improving local penetration and effectiveness while avoiding systemic absorption.
3Reliability
If quinolone antibiotics are used in the external ear, then treatment is provided, but inner ear toxicity risk increases
Solution Approach 1:
The patent employs local quality by designing a formulation where finafloxacin is delivered topically to the external ear with properties optimized for local action. The compound demonstrates selective activity at the site of infection while maintaining low potential for inner ear toxicity through appropriate formulation and dosing.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.